Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

According to the 6 industry analysts covering Novavax, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$82m ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Novavax Inc. closed 63.58% short of its 52-week high of $23.86, which the company reached on June 6th.

This makes it worthwhile to examine what the stock has in store. Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Novavax shares fell 11.2% during ... are currently trading – either way it allows you to profit off of the share price decline. According to data from Benzinga Pro, NVAX has a 52-week high ...

Novavax shares are trading higher by 13.5% ... currently trading – either way it allows you to profit off of the share price decline. According to data from Benzinga Pro, NVAX has a 52-week ...

Shares of Novavax Inc. NVAX slipped 2.99% to $8.43 Monday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% to ...

A higher fair value than the current market price drives investors ... For the current quarter, Novavax is expected to post a loss of $0.67 per share, indicating a change of +53.5% from the ...

This makes it worthwhile to examine what the stock has in store. Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate ...